Biogen’s Alzheimer drug slows mental decline

March 22, 2015 10:01 PM

3 0

Biogen Idec Inc (NASDAQ:BIIB) drug that attacks plaque buildup in the human brain slowed cognitive decline in patients that were in early phase of Alzheimer disease. The results were revealed in a small, early-stage study carried out by the company that tracked patients over 54 weeks. The news took Biogen’s share price to all-time highs.

In December, Biogen stated that its drug named ‘aducanumab’ resulted in a statistically noteworthy effect on cognition and intends to commence a late-stage trial later this year that will include over 1,000 patients. It used two cognitive tests in early stage trial to evaluate aducanumab’s clinical ...

Also read: Trump revels in the secretary of state show

Read more

To category page

Loading...